Search

everythinglearnresearchcommunity

for

Search:↓

Different types of hair loss in lupus need careful diagnosis for proper treatment.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.

Type I interferons play a key role in the development of various skin diseases.

The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.

The document concludes that treating tough skin disease in lupus involves sun protection, steroids, antimalarials, and various other therapies chosen based on individual risks and benefits.

The European Society of Cutaneous Lupus Erythematosus created a questionnaire to standardize patient assessment and improve care for cutaneous lupus.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

An imbalance in gut bacteria is linked to skin immune diseases and may affect their outcomes and related health issues.

A woman with severe angioedema improved significantly after treatment with rituximab.

Lupus treatment requires a combination of drugs and therapies, with research needed for new options.

Hair loss in systemic lupus erythematosus patients is unique and improves with treatment.

Women with Systemic Lupus Erythematosus should have closely monitored pregnancies and avoid certain medications to improve their pregnancy outcomes.

Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Psychotropic medications can cause skin problems but also treat some skin conditions.

Hair loss can indicate or worsen with systemic diseases, and treating the underlying condition is important.

People with lupus and rheumatoid arthritis have thinner hair than healthy people.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

Pharmacists should interpret lab data and perform physical exams to improve patient care.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Mnemonics help improve memory in dermatology by up to 50%.

A child with low platelets and anemia was later found to have lupus.

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.

Gender-specific analysis could improve treatment for childhood systemic lupus erythematosus.

A 50-year-old woman with breast cancer developed an autoimmune skin disorder, highlighting the need for thorough checks and team-based treatment.

Many patients with cutaneous lupus erythematosus experience hair loss and nail problems, which are important for diagnosis and treatment.

A woman in Sri Lanka was diagnosed with lupus after presenting with protein loss from the gut and other symptoms.

A man with four autoimmune diseases suggests a new category for multiple autoimmune syndrome.